Baader Bank Reiterates CHF 231 Price Target for Roche Holding Ltd. (ROG)
ROG has been the topic of several other research reports. J P Morgan Chase & Co reissued a buy rating on shares of Roche Holding in a research note on Wednesday, June 7th. Goldman Sachs Group, Inc. (The) set a CHF 335 target price on Roche Holding and gave the stock a buy rating in a research note on Saturday, May 20th. Jefferies Group LLC set a CHF 305 target price on Roche Holding and gave the stock a buy rating in a research note on Saturday, May 20th. UBS AG set a CHF 260 target price on Roche Holding and gave the stock a neutral rating in a research note on Thursday, July 6th. Finally, Deutsche Bank AG set a CHF 260 target price on Roche Holding and gave the stock a neutral rating in a research note on Friday, July 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of CHF 267.53.
Roche Holding (VTX:ROG) opened at 244.00 on Tuesday. The stock’s 50 day moving average price is CHK 243.56 and its 200 day moving average price is CHK 252.42. The stock has a market cap of CHK 208.20 billion and a price-to-earnings ratio of 21.66. Roche Holding has a 52 week low of CHK 218.30 and a 52 week high of CHK 273.00.
TRADEMARK VIOLATION WARNING: “Baader Bank Reiterates CHF 231 Price Target for Roche Holding Ltd. (ROG)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/baader-bank-reiterates-chf-231-price-target-for-roche-holding-ltd-rog/1562611.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.